NurExone management commentary says six months ended June 30, 2026 net loss narrows as lower G&A offsets higher R&D spending

• NurExone management commentary for the six-month period ended June 30, 2026 reported a net loss of US$ 3.45 million, versus US$ 3.52 million.
• Research and development expense rose to US$ 1.38 million from US$ 1.32 million, led by higher salaries, partly offset by lower subcontractors.
• General and administrative expense fell to US$ 2.05 million from US$ 2.21 million, reflecting lower professional services and legal costs.
• Current assets declined to US$ 1.16 million from US$ 2.6 million, driven mainly by lower cash and cash equivalents.
• Management flagged a going-concern uncertainty, citing expected ongoing losses and insufficient funds to finance planned operations for 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief on August 30, 2026, and is solely responsible for the information contained therein.